Purple Biotech annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Purple Biotech R&D Spending Growth & History (PPBT)
Purple Biotech's r&d spending was $3.7M for fiscal 2025.
View full Purple Biotech company overviewPurple Biotech annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.7M | −$3.9M | −51.04% |
| 2024 | 2024-12-31 | $7.6M | −$9.4M | −55.27% |
| 2023 | 2023-12-31 | $17.0M | $714,000 | +4.38% |
| 2022 | 2022-12-31 | $16.3M | $4.5M | +37.99% |
| 2021 | 2021-12-31 | $11.8M | $4.6M | +63.40% |
| 2020 | 2020-12-31 | $7.2M | $5.0M | +217.73% |
| 2019 | 2019-12-31 | $2.3M | −$3.0M | −56.76% |
| 2018 | 2018-12-31 | $5.3M | $628,000 | +13.53% |
| 2017 | 2017-12-31 | $4.6M | $460,000 | +11.00% |
| 2016 | 2016-12-31 | $4.2M | $1.6M | +63.28% |
| 2015 | 2015-12-31 | $2.6M | — | — |
Purple Biotech quarterly r&d spending
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $702,000 | $149,000 | +26.94% |
| Q1 2026 | 2026-03-31 | $1.2M | — | — |
| Q4 2025 | 2025-12-31 | $1.8M | — | — |
| Q3 2025 | 2025-09-30 | $587,000 | — | — |
| Q2 2025 | 2025-06-30 | $553,000 | — | — |
Purple Biotech r&d spending trends
Over the last five fiscal years, Purple Biotech's r&d spending decreased from $7.2M to $3.7M, a change of −$3.5M. The latest reported quarter, Q2 2026, shows $702,000.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Purple Biotech source filings ↗